Prolivia is developing injectable biotherapeutics to inhibit disease progression locally. Its products are based on a proprietary HYALUTE™ microparticle technology that enables highly localized mechanical support and controlled release of biotherapeutics to diseased tissues.
Prolivia
Prolivia is developing next generation injectable HA and HA combination products.